

ASX Announcement

11 November 2020

Clarification on Quarterly Activity Report and Appendix 4C

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, provides a clarification on its recent Quarterly Activity Report and Appendix 4C lodged 30 October 2020.

In addition to the business update commentary that was provided in the Quarterly Activity Report and further to the information in the Appendix 4C under 'Payments to related parties of the entity and their associates' (Item 6), Regeneus confirms that \$536k was paid to related parties during the July – September quarter. This consisted of \$65k in Non-Executive Director fees, for the period April to June 2020, and \$471k in executive remuneration, including the \$325k bonus paid to former CEO Leo Lee for finalizing the Kyocera contract (as announced on 3 September 2020).

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com